Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-448 Safety and Efficacy in Prostate Cancer
NCT01132404Phase 2Terminated
- Sponsor
- Millennium Pharmaceuticals
- Start
- Nov 2010
- Primary completion
- Sep 2011
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TAK-448 in prostate cancer (PCa), sponsored by Millennium Pharmaceuticals. Started Nov 2010; status: terminated.
02
Drugs
TAK-448
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01132404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01132404.